Home - Translational Andrology and Urology

Ejaculatory Dysfunction

Over the past two decades our understanding of ejaculatory dysfunction has evolved from the initial premise that these conditions were almost exclusively due psychological factors to a new understanding. We now understand that men with lifelong premature ejaculation may have an underlying genetic predisposition to rapid ejaculation and that men with acquired premature ejaculation may have, in addition to a variety of psychorelational factors including global anxiety, sexual performance anxiety and depression, be also suffering comorbid erectile dysfunction, chronic prostatitis and a variety of less common conditions including hyperthyroidism.

Peyronie’s Disease edited by Dr. Wayne J. G. Hellstrom and Dr. Faysal A. Yafi

PD is a fibrotic condition of the tunica albuginea of the penis, and is familiar to urologists throughout the world. PD is a wound healing disorder that has a variable and heterogeneous clinical presentation, with any combination of penile plaque(s), curvature, pain, and erectile dysfunction (ED).

Testimonials from Prominent Physician Investigator

Prominent physician investigators, including editorial board members, authors, and readers, who know the journal well, provided testimonials for TAU. We are thankful for their support for the journal.

Focused Issue: Interstitial Cystitis/Painful Bladder Syndrome edited by Drs. Grannum R. Sant and Ricardo Saban

Dr. Grannum R. Sant（Left）. Guest editor of focused issue “Interstitial Cystitis/Painful Bladder Syndrome” , Tufts University School of Medicine, USA. Dr. Ricardo Saban(Right). Guest editor of focused issue “Interstitial Cystitis/Painful Bladder Syndrome”, University Anhembi Morumbi, S. Paulo, Brazil. Dr. Sant and Saban strove to present a current, state-of-the-art and global perspective on this chronic and potentially debilitating disease. The papers in this focused issue of the TAU journal issue provide insightful updates and perspectives on the epidemiology, pathophysiology and mechanistic aspects of this enigmatic disease, overviews of IC diagnosis and treatment in India and Japan and patient advocacy group contributions from the US and European Union (EU).

Treatment of painful bladder syndrome/interstitial cystitis with botulinum toxin A: why isn’t it effective in all patients?

BTA is a neurotoxin produced by the bacteria Clostridium botulinum. Several serotypes of the toxin are produced, among which type A is the most potent. BTA is a zinc-dependent endopeptidase, which binds to and is taken up by, neurons via a high-affinity interaction with synaptic vesicle protein 2 (SV2). Additionally, there are low-affinity interactions with polysialogangliosides on the surface of the cell that facilitate entry of BTA. The intracellular substrate of the type A toxin used clinically is the synaptosomal-associated protein of 25 kDa (SNAP-25), a member of the SNARE protein superfamily necessary for docking and fusion of synaptic vesicles that mediate release of neurotransmitters, including acetylcholine (ACh).

Intravesical liposome drug delivery and IC/BPS

Most of the therapeutic agents for functional bladder disorders are administered orally. These medications may be poorly absorbed and/or metabolized by the liver, and they often fail to have a therapeutic effect at the diseased bladder wall without also producing significant unwanted systemic side effects. Their primary elimination route may not be through the urinary system, which further reduces the amount of drug delivered to the urothelium. The rationale for intravesical treatment for IC/BPS is to apply an effective dose of a therapeutic drug to the diseased organ and only to that organ.

Increased bladder permeability in interstitial cystitis/painful bladder syndrome

Finding effective treatments would be greatly improved if patients could be stratified into more homogeneous groups for clinical trials. An effective method of measuring bladder permeability could also represent an important step forward in this regard because it could offer an improved diagnostic as well as an objective measure of response to therapy that could be used to optimize therapies. Our group has recently shown that MRI can clearly demonstrate increased bladder permeability that correlates with patient condition. The mechanisms by which information concerning the status of one pelvic organ is communicated to another, and how this information affects the other organ is critical to know and is being actively investigated by a number of groups. Finally, understanding the role of the brain, stress, and past life experiences also needs to be investigated.

Clinical presentation and treatment of bladder pain syndrome/interstitial cystitis (BPS/IC) in India

Hunner’s lesion is a distinctive inflammatory lesion with characteristics central fragility, which ruptures on hydrodistension. It is usually a solitary lesion but 2-3 lesions may be present. This lesion is typically visible before the bladder is distended. On cystoscopy, it appears as a circumscript reddened mucosal area with small vessels radiating towards a central scar. This site ruptures with increasing bladder distension; with petechial oozing blood from the lesion in a waterfall fashion. In our series of more than 250 cystoscopies in BPS/IC patients, a typical Hunner’s lesion has rarely been observed. In our series we have seen red patches but accompanied by patechiae and ecchymosis all over the bladder and not sure if it is Hunner’s lesion.

A step forward: Translational Andrology and Urology is indexed in PubMed/PMC

By December 5th, 2015, the Translational Andrology and Urology (TAU) has passed all the evaluation required by PubMed Centre (PMC) and is officially accepted for inclusion in PubMed/PMC - an extensive and important biomedical online journal repository. All previously published content on TAU will be searchable within 1-2 months. Consequently, authors publishing in TAU will enjoy maximum exposure of their research. Acceptance in this prominent database speaks highly to the quality of the published work and the journal’s significant potential.

Urodynamic and physiologic patterns associated with the common causes of neurogenic bladder in adults

Schematic showing the determination of detrusor pressure or Pdet. The detrusor contribution to voiding is calculated by subtracting the abdominal pressure (Pabd; estimated as rectal pressure) from total intravesical pressure (Pves).

Management options for sphincteric deficiency in adults with neurogenic bladder

Young–Dees–Leadbetter repair—involves lengthening the urethra, often some narrowing up to or including the trigone, with excision of bladder mucosa and wrapping of the repair with detrusor muscle leaflets.

Reconstructive techniques for creation of catheterizable channels: tunneled and nipple valve channels

“Yang-Monti” Channels. (A) Isolated 2 cm ileal segment; (B) detubularized ileal segment; (C) transversely retubularized ileal segment.

Brain-derived neurotrophic factor promotes nerve regeneration by activating the JAK/STAT pathway in Schwann cells

To validate the Schwann cell, the specific cellular markers S100 and p75 were checked by immunofluorescence staining in HSCs and RSCs RT4-D6P2T cells. The result indicated that both those cells expressed S100 and p75 in the cytoplasm, although the expression level and location are different. The HSCs expressed more S100 and p75, while the RSCs RT4-D6P2T shaped as small spindle-like cells and expressed peri-nucleus S100.

What do urologists think patients need to know when starting on androgen deprivation therapy? The perspective from Canada versus countries with lower gross domestic product

This figure shows ADT side effect management strategies in which significant differences in endorsement were found between urologists in Canada and urologists in lower GDP countries. Seven side effects had one or more management strategies that differed significantly between Canada and lower GDP countries

‹ ›

Vol 5, No 4 (August, 2016)

About tau

Manuscript Submission

Advertising

Contact us

General editorial enquiries:
Email: tau@amepc.org
Copyright related contact:
Email: permissions@amegroups.com
Commercial Sales contact (Reprints, advertising, etc.):
Email: sales@amegroups.com

eBooks

Focused Issues more

Dr. Chris G. McMahon: Ejaculatory Dysfunction (Vol 5, No 4, August 2016) More >>

Wayne JG. Hellstrom, Faysal A. Yafi: Peyronie’s Disease (Vol 5, No 3, June 2016) More >>

Drs. Charles Welliver, Tobias S. Köhler and Kevin T. McVary: Controversies and Current... More >>

Preface

Ejaculatory dysfunction

Chris G. McMahon

PDF Pages: 401 HTML

Review Article

Ejaculatory dysfunction—the evolution of a new understanding

Chris G. McMahon

PDF Pages: 402-408 HTML

The epidemiology of premature ejaculation

Theodore Robert Saitz, Ege Can Serefoglu

PDF Pages: 409-415 HTML

Classification and definition of premature ejaculation

Arie Parnham, Ege Can Serefoglu

PDF Pages: 416-423 HTML

The pathophysiology of lifelong premature ejaculation

Marcel D. Waldinger

PDF Pages: 424-433 HTML

The pathophysiology of acquired premature ejaculation

Chris G. McMahon, Emmanuele A. Jannini, Ege C. Serefoglu, Wayne J. G. Hellstrom

PDF Pages: 434-449 HTML

Ejaculatory dysfunction in the treatment of lower urinary tract symptoms

Kenneth Jackson DeLay, Max Nutt, Kevin T. McVary

PDF Pages: 450-459 HTML

The impact of ejaculatory dysfunction upon the sufferer and his partner

Carmita Helena Najjar Abdo

PDF Pages: 460-469 HTML

Patient reported outcomes in the assessment of premature ejaculation

Stanley E. Althof

PDF Pages: 470-474 HTML

Psychosexual therapy for premature ejaculation

Stanley E. Althof

PDF Pages: 475-481 HTML

The drug treatment of premature ejaculation

Shin-ichi Hisasue

PDF Pages: 482-486 HTML

Emerging and investigational drugs for premature ejaculation

Chris G. McMahon

PDF Pages: 487-501 HTML

Is there a place for surgical treatment of premature ejaculation?

Du Geon Moon

PDF Pages: 502-507 HTML

The design and methodology of premature ejaculation interventional studies

Chris G. McMahon

PDF Pages: 508-525 HTML

The office management of ejaculatory disorders

Bang-Ping Jiann

PDF Pages: 526-540 HTML

Epidemiology of delayed ejaculation

Stefania Di Sante, Daniele Mollaioli, Giovanni Luca Gravina, Giacomo Ciocca, Erika Limoncin, Eleonora Carosa, Andrea Lenzi, Emmanuele A. Jannini

PDF Pages: 541-548 HTML

The pathophysiology of delayed ejaculation

Juza Chen

PDF Pages: 549-562 HTML

Psychosexual therapy for delayed ejaculation based on the Sexual Tipping Point model

Michael A. Perelman

PDF Pages: 563-575 HTML

The drug treatment of delayed ejaculation

Ibrahim A. Abdel-Hamid, Moustafa A. Elsaied, Taymour Mostafa

PDF Pages: 576-591 HTML

Retrograde ejaculation, painful ejaculation and hematospermia

Arie Parnham, Ege Can Serefoglu

PDF Pages: 592-601 HTML

Post orgasmic illness syndrome (POIS)

Marcel D. Waldinger

PDF Pages: 602-606 HTML

Opinion

Surgery is not indicated for the treatment of premature ejaculation

James Anaissie, Faysal A. Yafi, Wayne J. G. Hellstrom

PDF Pages: 607-612 HTML

Commentary

Commentary on genitourinary cancer survivorship: physical activity and prostate cancer survivorship

Garjae Lavien, Uwais Zaid, Andrew C. Peterson

PDF Pages: 613-615 HTML

Editorial

Screening for functional kinases in metastatic prostate cancer: a glimmer of hope for kinase inhibition

Moshe C. Ornstein, Jorge A. Garcia, Nima Sharifi

PDF Pages: 616-619 HTML

Meet the Professor

Professor Larry I. Lipshultz: genetic research in male infertility

Eunice X. Xu

PDF Pages: 620-621 HTML

Prof. Eric A. Klein: genomic research in prostate cancer

Eunice X. Xu

PDF Pages: 622-623 HTML

Prof. Allen Seftel: be part of new innovations

Skylar Gao

PDF Pages: 624-625 HTML

Dr. Jeffrey Tomaszewski: the application of prostate cancer genomic tests

Skylar Gao

PDF Pages: 626-627 HTML

Dr. Ryan P. Smith: management of chronic orchialgia

Lucine M. Gao

PDF Pages: 628-629 HTML

Prof. Rajeev Kumar: adrenal masses

Lucine M. Gao

PDF Pages: 630-631 HTML

Erratum

Erratum to comprehensive characterization of the perioperative morbidity of cytoreductive nephrectomy

Editorial Team

PDF Pages: 632 HTML

Review Article

Strategies for maintaining penile size following penile implant

King Chien Joe Lee, Gerald B. Brock

Phalloplasty for the genetic male

Giulio Garaffa, Gabriele Antonini, Vincenzo Gentile, David J. Ralph

Exogenous testosterone: a preventable cause of male infertility

Lindsey E. Crosnoe, Ethan Grober, Dana Ohl, Edward D. Kim

Premature ejaculation: do we have effective therapy?

Ege Can Serefoglu, Theodore R. Saitz, Landon Trost, Wayne J.G. Hellstrom

Peyronie’s disease: current therapy

Clay M. Pendleton, Run Wang

Expert Opinions on Challenging Cases

Commentary on the myths of Peyronie’s disease

Alex K Wu, Tom F Lue

Commentary

Randall plaque versus renal stone?

Thomas Chi, Joe Miller, Marshall L. Stoller

Original Article

Surgical treatment of Peyronie’s disease by modified 16-dot placation in China

Wen Ji Li, Haijun Yao, Ke Zhang, Zhikang Cai, Jun Da, Mingxi Xu, Zhong Wang

Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?

Sherif Azab, Ayman Osama, Mona Rafaat

Podium Lecture

PL 03. Male sexual function before and after urethral stricture surgery

Hong Li

Review Article

Role of hormonal therapy for prostate cancer: Perspective from Japanese experiences

Mikio Namiki, Satoru Ueno, Yasuhide Kitagawa

Premature ejaculation: do we have effective therapy?

Ege Can Serefoglu, Theodore R. Saitz, Landon Trost, Wayne J.G. Hellstrom

Expert Opinions on Challenging Cases

Commentary on high flow, non-ischemic, priapism

Alex K. Wu, Tom F. Lue

Original Article

Overall satisfaction, sexual function, and the durability of neophallus dimensions following staged female to male genital gender confirming surgery: the Institute of Urology, London U.K. experience

Maurice M. Garcia, Nim A. Christopher, Francesco De Luca, Marco Spilotros, David J. Ralph

Research Highlight

Extension of the therapeutic spectrum in castration-resistant prostate cancer: Osteoclast inhibition with denosumab

Johannes M. Wolff, Hans-Peter Schmid

Editorials

Enzalutamide (formerly MDV3100) prolongs survival in docetaxel-pretreated castration-resistant prostate cancer patients

Matthias M. Heck, Jürgen E. Gschwend, Margitta Retz

Original Articles

VEGF is associated with the poor survival of patients with prostate cancer: a meta-analysis

Ping Zhan, Ya-Nan Ji, Li-Ke Yu

Review Articles

The role of microRNAs in prostate cancer progression

U-Ging Lo, Diane Yang, Jer-Tsong Hsieh

Androgen receptor-mediated non-genomic regulation of prostate cancer cell proliferation

Ross S. Liao, Shihong Ma, Lu Miao, Rui Li, Yi Yin, Ganesh V. Raj

Review Article

Future perspectives of prostate cancer therapy

Murali Gururajan, Edwin M. Posadas, Leland W. K. Chung

Small RNA and its application in andrology and urology

Ji Wang, Long-Cheng Li

TGF-β mediated DNA methylation in prostate cancer

Chung Lee, Qiang Zhang, Xaolin Zi, Atreya Dash, Marcelo B Soares, Farahnaz Rahmatpanah, Zhenyu Jia, Michael McClelland, Dan Mercola

Cystine nephrolithiasis

Hasan Fattah, Yasmin Hambaroush, David S. Goldfarb

Outlining the limits of partial nephrectomy

Sameer Chopra, Raj Satkunasivam, Chandan Kundavaram, Gangning Liang, Inderbir S. Gill

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)

Thenappan Chandrasekar, Joy C. Yang, Allen C. Gao, Christopher P. Evans

Prostate cancer metastasis: roles of recruitment and reprogramming, cell signal network and three-dimensional growth characteristics

Shabnam Ziaee, Gina Chia-Yi Chu, Jen-Ming Huang, Shirly Sieh, Leland W. K. Chung

Inflammation in prostate cancer progression and therapeutic targeting

Timothy Stark, Lydia Livas, Natasha Kyprianou

Sympathetic nervous system and chronic bladder pain: a new tune for an old song

Ana Charrua, Rui Pinto, Lori Ann Birder, Francisco Cruz

Angiogenic factors, bladder neuroplasticity and interstitial cystitis—new pathobiological insights

Ricardo Saban

Increased bladder permeability in interstitial cystitis/painful bladder syndrome

Robert E. Hurst, Beverley Greenwood-Van Meerveld, Amy B. Wisniewski, Samuel VanGordon, Hsueh Kung Lin, Bradley P. Kropp, Rheal A. Towner

Editorial

PIVOT and the challenges of localized prostate cancer care

Aviva E. Weinberg, James D. Brooks

Original Article

Overall satisfaction, sexual function, and the durability of neophallus dimensions following staged female to male genital gender confirming surgery: the Institute of Urology, London U.K. experience

Maurice M. Garcia, Nim A. Christopher, Francesco De Luca, Marco Spilotros, David J. Ralph

Research Highlights

Enzalutamide: the emperor of all anti-androgens

Emmanuel S. Antonarakis

Review Articles

Androgen receptor gene mutation, rearrangement, polymorphism

Kurtis Eisermann, Dan Wang, Yifeng Jing, Laura E. Pascal, Zhou Wang

Androgen receptor epigenetics

Changmeng Cai, Xin Yuan, Steven P. Balk

Androgen receptor genomic regulation

Hong-Jian Jin, Jung Kim, Jindan Yu

Decoding the androgen receptor splice variants

Changxue Lu, Jun Luo

Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression

Campbell M. Grant, Natasha Kyprianou

Steroid hormone synthetic pathways in prostate cancer

Elahe A. Mostaghel

Near-infrared fluorescence and nuclear imaging and targeting of prostate cancer

Jason Wu, Dongfeng Pan, Leland W.K. Chung

Mini-Review

Multi-peptide immunotherapeutic vaccine for renal cell carcinoma: getting the troops all worked up

Kavitha Yaddanapudi, John W. Eaton

Review Article

Kidney stone risk following Roux-en-Y gastric bypass surgery

Benjamin K. Canales, Ricardo D. Gonzalez

Review Article

Reactive oxygen species, inflammation and calcium oxalate nephrolithiasis

Saeed R. Khan

Review Article: Hypospadias

Do endocrine disruptors cause hypospadias?

Sisir Botta, Gerald R. Cunha, Laurence S. Baskin

Below are the latest Translational Andrology and Urology articles published online ahead of print publication.

Review Article

Female with bladder cancer: what and why is there a difference?

Phillip Marks, Armin Soave, Shahrokh F. Shariat, Harun Fajkovic, Margit Fisch, Michael Rink

Lynch syndrome and exposure to aristolochic acid in upper-tract urothelial carcinoma: its clinical impact?

Pierre Colin, Thomas Seisen, Romain Mathieu, Sharohkh F. Shariat, Morgan Rouprêt

Immunotherapy in urothelial carcinoma: fade or future standard?

Johannes Breyer, Maximilian Burger, Wolfgang Otto

How to optimally manage elderly bladder cancer patients?

Francesco Soria, Marco Moschini, Stephan Korn, Shahrokh F. Shariat

Genetics and biological markers in urachal cancer

Mark A. Behrendt, Bas W. G. van Rhijn

Why are upper tract urothelial carcinoma two different diseases?

Tibor Szarvas, Orsolya Módos, András Horváth, Péter Nyirády

Variant histology in bladder cancer: how it should change the management in non-muscle invasive and muscle invasive disease?

Yvonne Klaile, Katrin Schlack, Martin Boegemann, Julie Steinestel, Andres Jan Schrader, Laura-Maria Krabbe

Hypogonadism and testosterone replacement therapy in end-stage renal disease (ESRD) and transplant patients

Grace Snyder, Daniel A. Shoskes

Effects of varicocelectomy on serum testosterone

Patrick Whelan, Laurence Levine

Pharmacology of testosterone replacement therapy preparations

Jennifer J. Shoskes, Meghan K. Wilson, Michael L. Spinner

Testosterone replacement in the infertile man

Ahmad Majzoub, Edmund Sabanegh Jr

Malignancy in disorders of sex development

Martin Kathrins, Thomas F. Kolon

Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider?

Paul Sargos, Brian C. Baumann, Libni J. Eapen, Amit Bahl, Vedang Murthy, Guilhem Roubaud, Mathieu Orré, Jason A. Efstathiou, Shahrokh Shariat, Stephane Larré, Pierre Richaud, John P. Christodouleas

The controversy surrounding penile rehabilitation after radical prostatectomy

Jonathan Clavell-Hernández, Run Wang

Off label therapies for testosterone replacement

Lorenzo DiGiorgio, Hossein Sadeghi-Nejad

Testosterone replacement therapy and voiding dysfunction

Wesley Baas, Tobias S. Köhler

Erectile dysfunction, masculinity, and psychosocial outcomes: a review of the experiences of men after prostate cancer treatment

Suzanne K. Chambers, Eric Chung, Gary Wittert, Melissa K. Hyde

Testosterone therapy and prostate cancer

Alexander W. Pastuszak, Katherine M. Rodriguez, Taylor M. Nguyen, Mohit Khera

Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery

Mohammad Abufaraj, Kilian Gust, Marco Moschini, Beat Foerster, Francesco Soria, Romain Mathieu, Shahrokh F. Shariat

Adult-onset hypogonadism: evaluation and role of testosterone replacement therapy

Andrew J. Davidiuk, Gregory A. Broderick

Risk stratification for kidney sparing procedure in upper tract urothelial carcinoma

Zine-Eddine Khene, Romain Mathieu, Solène-Florence Kammerer-Jacquet, Thomas Seisen, Morgan Roupret, Shahrokh F. Shariat, Benoit Peyronnet, Karim Bensalah